Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Shortened Regimens for First Diagnosed Smear Positive Drug Susceptible Pulmonary Tuberculosis: a Randomised Controlled Non-inferiority Trial
Brief Summary: The purpose of the study is to evaluate the safety and efficacy of two shortened regimens for newly diagnosed smear positive drug susceptible pulmonary tuberculosis in comparison to World Health Organization recommended standard 6-month regimen.


Options:
A: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 4; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 5; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 6 (optional); Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Linezolid Cohort; Type: EXPERIMENTAL; Interventions: Drug: Linezolid | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 3 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 4 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 5 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 5 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 6 (optional) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 6 (optional) | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid Cohort
B: Arm Label: Cohort 1, Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 1, Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 1, Sequence 3; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 2, Sequence 1; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 2, Sequence 2; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Arm Label: Cohort 2, Sequence 3; Type: EXPERIMENTAL; Interventions: Drug: PNU-100480, Drug: Placebo | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1, Sequence 1 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1, Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Sequence 1 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1, Sequence 2 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1, Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Sequence 2 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1, Sequence 3 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 1, Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 1, Sequence 3 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 1 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 1 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2, Sequence 1 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 2 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 2 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2, Sequence 2 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 3 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 3 | Intervention Type: DRUG; Name: PNU-100480; Assigned to Arm(s): Cohort 2, Sequence 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cohort 2, Sequence 3
C: Arm Label: experimental group1; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid, Drug: Rifampicin, Drug: Pyrazinamide, Drug: Ethambutol, Drug: Levofloxacin | Arm Label: experimental group2; Type: EXPERIMENTAL; Interventions: Drug: Isoniazid, Drug: Rifampicin, Drug: Pyrazinamide, Drug: Ethambutol | Arm Label: Control regimen group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Isoniazid, Drug: Rifampicin, Drug: Pyrazinamide, Drug: Ethambutol | Intervention Type: DRUG; Name: Isoniazid; Assigned to Arm(s): Control regimen group, experimental group1, experimental group2 | Intervention Type: DRUG; Name: Rifampicin; Assigned to Arm(s): Control regimen group, experimental group1, experimental group2 | Intervention Type: DRUG; Name: Pyrazinamide; Assigned to Arm(s): Control regimen group, experimental group1, experimental group2 | Intervention Type: DRUG; Name: Ethambutol; Assigned to Arm(s): Control regimen group, experimental group1, experimental group2 | Intervention Type: DRUG; Name: Levofloxacin; Assigned to Arm(s): experimental group1
D: Arm Label: Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg); Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (M), Drug: Pretomid (Pa), Drug: Pyrazinamide (Z) | Arm Label: Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg); Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (M), Drug: Pretomid (Pa), Drug: Pyrazinamide (Z) | Arm Label: Drug Sensitive: Rifafour; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rifafour | Arm Label: Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg); Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (M), Drug: Pretomid (Pa), Drug: Pyrazinamide (Z) | Intervention Type: DRUG; Name: Moxifloxacin (M); Assigned to Arm(s): Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg), Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg), Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | Intervention Type: DRUG; Name: Pretomid (Pa); Assigned to Arm(s): Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg), Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg), Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | Intervention Type: DRUG; Name: Pyrazinamide (Z); Assigned to Arm(s): Drug Sensitive: M (400 mg) Pa (100 mg) Z (1500 mg), Drug Sensitive: M (400 mg) Pa (200 mg) Z (1500 mg), Multi Drug-Resistant: M (400 mg) Pa (200 mg) Z (1500 mg) | Intervention Type: DRUG; Name: Rifafour; Assigned to Arm(s): Drug Sensitive: Rifafour

Answer: C